pre-IPO PHARMA

COMPANY OVERVIEW

Artios is a leading DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. The Company, founded by SV Health Investors in 2016, is led by an experienced scientific and leadership team with proven expertise in DDR drug discovery.


LOCATION

  • Cambridge, , UK

  • THERAPEUTIC AREAS

  • Oncology

  • WEBSITE

    https://www.artiospharma.com


    CAREER WEBSITE

    None


    SOCIAL MEDIA


    INVESTORS

    abbvie-ventures andera-partners arix-bioscience ip-group life-science-partners m-ventures novartis-venture-fund pfizer-ventures sv-health-investors


    PRESS RELEASES


    Feb 9, 2023

    Artios Announces Initiation of Phase 2 Randomized Trial for ATR Inhibitor ART0380 plus Gemcitabine in Patients with Platinum Resistant Ovarian Cancer


    Aug 10, 2022

    Artios initiates Phase 2 study of Polθ Inhibitor ART4215 in Combination with PARP Inhibitor Talazoparib in BRCA Deficient Breast Cancer


    Jun 23, 2022

    Artios Appoints Samantha Truex to Board of Directors


    Apr 5, 2022

    Artios Announces ATR Inhibitor, ART0380, Development On Track and Progressing Into Phase 1b Evaluation


    Nov 16, 2021

    Artios Appoints Nora Brennan to Board of Directors and Audit Committee Chair


    For More Press Releases


    Google Analytics Alternative